Skip to main content
SpringerLink
Log in

Biomarkers

  • Protocol
  • First Online:
Book cover Computational Toxicology

Part of the book series: Methods in Molecular Biology ((MIMB,volume 930))

Abstract

Biomarkers are characteristics objectively measured and evaluated as indicators of: normal biologic processes, pathogenic processes, or pharmacologic response(s) to a therapeutic intervention. In environmental research and risk assessment, biomarkers are frequently referred to as indicators of human or environmental hazards. Discovering and implementing new biomarkers for toxicity caused by exposure to a chemical either from a therapeutic intervention or accidentally through the environment continues to be pursued through the use of animal models to predict potential human effects, from human studies (clinical or epidemiologic) or biobanked human samples, or the combination of all such approaches. The key to discovering or inferring biomarkers through computational means involves the identification or prediction of the molecular target(s) of the chemical(s) and the association of these targets with perturbed biological pathways. Two examples are given in this chapter: (1) inferring potential human biomarkers from animal toxicogenomics data, and (2) the identification of protein targets through computational means and associating these in one example with potential drug interactions and in another case with increasing the risk of developing certain human diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Johnson DE, Smith DA, Park BK (2007) Biomarkers: the pièce de résistance of innovative medicines. Curr Opin Drug Discov Devel 10:22–24

    PubMed  CAS  Google Scholar 

  2. Daly AK (2007) Individualized drug therapy. Curr Opin Drug Discov Devel 10:29–36

    PubMed  CAS  Google Scholar 

  3. Walker DB (2006) Serum chemical biomarkers of cardiac injury for nonclinical safety testing. Toxicol Pathol 34:94–104

    Article  PubMed  CAS  Google Scholar 

  4. Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3–7

    Article  PubMed  CAS  Google Scholar 

  5. Frank R, Hargreaves R (2003) Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2:566–580

    Article  PubMed  CAS  Google Scholar 

  6. Johnson DE, Rodgers AD, Sudarsanam S (2006) Future of computational toxicology: broad application into human disease and therapeutics. John Wiley & Sons, Inc, Hoboken, NJ

    Google Scholar 

  7. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:1054–1061

    Article  PubMed  CAS  Google Scholar 

  8. Johnson DE, Smith DA, Park BK (2009) Pharmacogenomics and adverse drug reactions; prospective screening for risk identification. Curr Opin Drug Discov Devel 12:27–30

    PubMed  CAS  Google Scholar 

  9. Ingelman-Sundberg M (2008) Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 358:637–639

    Article  PubMed  CAS  Google Scholar 

  10. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med 359:789–799

    Article  PubMed  CAS  Google Scholar 

  11. Office of the commissioner safety alerts for human medical products - Phenytoin (marketed as dilantin, phenytek and generics) and fosphenytoin sodium (marketed as Cerebyx and generics), http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm094919.htm

  12. Chiao SK, Romero DL, Johnson DE (2009) Current HIV therapeutics: mechanistic and chemical determinants of toxicity. Curr Opin Drug Discov Devel 12:53–60

    PubMed  CAS  Google Scholar 

  13. Bonnet E, Bernard J, Fauvel J, Massip P, Ruidavets J, Perret B (2008) Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients. AIDS Res Hum Retroviruses 24:169–171

    Article  PubMed  CAS  Google Scholar 

  14. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Eng J Med 351:2817–2826

    Article  CAS  Google Scholar 

  15. Wallach I, Jaitly N, Lilien R (2010) A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways. PLoS One 5:e12063

    Article  PubMed  Google Scholar 

  16. Milletti F, Vulpetti A (2010) Predicting polypharmacology by binding site similarity: from kinases to the protein universe. J Chem Inf Model 50:1418–1431

    Article  PubMed  CAS  Google Scholar 

  17. Critical Path Institute, http://www.c-path.org/

  18. www.pharmaadme.org - Home, http://pharmaadme.org/joomla/

  19. Genome Canada, http://www.genomecanada.ca/

  20. Drug Induced Liver Injury Network — DILIN site, https://dilin.dcri.duke.edu/

  21. The pharmacogenomics knowledge base [PharmGKB], http://pharmgkb.org/

  22. Waters MD, Fostel JM (2004) Toxicogenomics and systems toxicology: aims and prospects. Nat Rev Genet 5:936–948

    Article  PubMed  CAS  Google Scholar 

  23. Thompson Reuters Genego http://www.genego.com/

  24. Ekins S (2006) Systems-ADME/Tox: resources and network approaches. J Pharmacol Toxicol Methods 53:38–66

    Article  PubMed  CAS  Google Scholar 

  25. Davis AP, King BL, Mockus S, Murphy CG, Saraceni-Richards C, Rosenstein M, Wiegers T, Mattingly CJ (2011) The comparative toxicogenomics database: update 2011. Nucleic Acids Res 39:D1067–D1072

    Article  PubMed  Google Scholar 

  26. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM (2004) Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 101:9309–9314

    Article  PubMed  CAS  Google Scholar 

  27. Mattingly CJ, Rosenstein MC, Davis AP, Colby GT, Forrest JN, Boyer JL (2006) The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks. Toxicol Sci 92:587–595

    Article  PubMed  CAS  Google Scholar 

  28. The gene ontology, http://www.geneontology.org/

  29. GoMiner Home Page, http://discover.nci.nih.gov/gominer/index.jsp

  30. Currie RA, Bombail V, Oliver JD, Moore DJ, Lim FL, Gwilliam V, Kimber I, Chipman K, Moggs JG, Orphanides G (2005) Gene ontology mapping as an unbiased method for identifying molecular pathways and processes affected by toxicant exposure: application to acute effects caused by the rodent non-genotoxic carcinogen diethylhexylphthalate. Toxicol Sci 86:453–469

    Article  PubMed  CAS  Google Scholar 

  31. Yu X, Griffith WC, Hanspers K, Dillman JF, Ong H, Vredevoogd MA, Faustman EM (2006) A system-based approach to interpret dose- and time-dependent microarray data: quantitative integration of gene ontology analysis for risk assessment. Toxicol Sci 92:560–577

    Article  PubMed  CAS  Google Scholar 

  32. Xirasagar S, Gustafson SF, Huang C, Pan Q, Fostel J, Boyer P, Merrick BA, Tomer KB, Chan DD, Yost KJ, Choi D, Xiao N, Stasiewicz S, Bushel P, Waters MD (2006) Chemical effects in biological systems (CEBS) object model for toxicology data, SysTox-OM: design and application. Bioinformatics (Oxford, England) 22:874–882

    Article  CAS  Google Scholar 

  33. Mao X, Cai T, Olyarchuk JG, Wei L (2005) Automated genome annotation and pathway identification using the KEGG Orthology (KO) as a controlled vocabulary. Bioinformatics (Oxford, England) 21:3787–3793

    Article  CAS  Google Scholar 

  34. Hoffmann R, Valencia A (2003) Life cycles of successful genes. Trends Genet 19:79–81

    Article  PubMed  CAS  Google Scholar 

  35. Hoffmann R, Valencia A (2003) Protein interaction: same network, different hubs. Trends Genet 19:681–683

    Article  PubMed  CAS  Google Scholar 

  36. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF (2005) A network-based analysis of systemic inflammation in humans. Nature 437:1032–1037

    Article  PubMed  CAS  Google Scholar 

  37. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI (2005) Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 65:8679–8689

    Article  PubMed  CAS  Google Scholar 

  38. Reactome, http://www.reactome.org/

  39. KEGG: Kyoto encyclopedia of genes and genomes, http://www.genome.jp/kegg/

  40. DrugBank: home, http://www.drugbank.ca/

  41. Remm M, Storm CE, Sonnhammer EL (2001) Automatic clustering of orthologs and in-paralogs from pairwise species comparisons. J Mol Biol 314:1041–1052

    Article  PubMed  CAS  Google Scholar 

  42. Kim DH, Ausubel FM (2005) Evolutionary perspectives on innate immunity from the study of Caenorhabditis elegans. Curr Opin Immunol 17:4–10

    Article  PubMed  CAS  Google Scholar 

  43. Kelley BP, Sharan R, Karp RM, Sittler T, Root DE, Stockwell BR, Ideker T (2003) Conserved pathways within bacteria and yeast as revealed by global protein network alignment. Proc Natl Acad Sci USA 100:11394–11399

    Article  PubMed  CAS  Google Scholar 

  44. Kharasch ED, Schroeder JL, Bammler T, Beyer R, Srinouanprachanh S (2006) Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (“compound A”) in rats. Toxicol Sci 90:419–431

    Article  PubMed  CAS  Google Scholar 

  45. Duffy CM, Matta BF (2000) Sevoflurane and anesthesia for neurosurgery: a review. J Neurosurg Anesthesiol 12:128–140

    Article  PubMed  CAS  Google Scholar 

  46. Bedford RF, Ives HE (2000) The renal safety of sevoflurane. Anesth Analg 90:505–508

    Article  PubMed  CAS  Google Scholar 

  47. Vaidya VS, Ferguson MA, Bonventre JV (2008) Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 48:463–493

    Article  PubMed  CAS  Google Scholar 

  48. Carlson EA, McCulloch C, Koganti A, Goodwin SB, Sutter TR, Silkworth JB (2009) Divergent transcriptomic responses to aryl hydrocarbon receptor agonists between rat and human primary hepatocytes. Toxicol Sci 112:257–272

    Article  PubMed  CAS  Google Scholar 

  49. Chan E, Tan M, Xin J, Sudarsanam S, Johnson DE (2010) Interactions between traditional Chinese medicines and Western therapeutics. Curr Opin Drug Discov Devel 13:50–65

    PubMed  CAS  Google Scholar 

  50. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LFA, de Jong D, Van de Vijver MJ, Van’t Veer LJ, Peterse JL (2008) Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216:141–150

    Article  PubMed  CAS  Google Scholar 

  51. Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321–345

    Article  PubMed  CAS  Google Scholar 

  52. Williams JA, Phillips DH (2000) Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res 60:4667–4677

    PubMed  CAS  Google Scholar 

  53. Kretschmer XC, Baldwin WS (2005) CAR and PXR: xenosensors of endocrine disrupters? Chem Biol Interact 155:111–128

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emiliem, Inc., San Francisco, CA, USA

    Harmony Larson, Elena Chan, Sucha Sudarsanam & Dale E. Johnson

Authors
  1. Harmony Larson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sucha Sudarsanam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dale E. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dale E. Johnson .

Editor information

Editors and Affiliations

  1. School of Biomedical Engineering, Chemical & Biological Engineering, Colorado State University, Campus Delivery 1370, Fort Collins, 80523-1370, Colorado, USA

    Brad Reisfeld

  2. , Chemical & Biological Engineering, Colorado State University, Campus Delivery 1370, Fort Collins, 80523-1370, Colorado, USA

    Arthur N. Mayeno

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Larson, H., Chan, E., Sudarsanam, S., Johnson, D.E. (2013). Biomarkers. In: Reisfeld, B., Mayeno, A. (eds) Computational Toxicology. Methods in Molecular Biology, vol 930. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-059-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-059-5_11

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-058-8

  • Online ISBN: 978-1-62703-059-5

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation